Split Cas9 System Detects Nucleic Acids at Attomolar Levels
A modular CRISPR-Cas9 approach offers rapid, amplification-free detection of DNA and RNA with single-nucleotide specificity.
Updated on Nov. 14, 2026 in Life Sciences

Researchers presented a split RNA-guided Cas9 system, called SCas9, for detecting nucleic acids. The system detects single-stranded DNA and RNA with picomolar sensitivity within 30 minutes, without amplification.
Why it matters
The limited trans-cleavage activity of conventional CRISPR-Cas9 has constrained its use in detection assays. SCas9 extends detection to double-stranded DNA, long RNA and microRNA, and was validated in clinical specimens including human papillomavirus 16 and miR-21 in colorectal cancer tissues.
The assay reports picomolar sensitivity within 30 minutes without amplification and attomolar sensitivity when amplification is added, as measured in laboratory conditions against the standard system's limited trans-cleavage activity. Sample sizes for the clinical validations and performance against existing diagnostic tests are not specified.
The details
Single-guide RNA is split into separate scaffold and spacer modules that function independently. Incorporating λ exonuclease allows detection of double-stranded DNA without requiring a protospacer adjacent motif (PAM) and without cis-cleavage activity.
Timeline
The core event was reported on November 14, 2026.
Deeper Dive
The split guide RNA design builds on the standard CRISPR-Cas9 platform, whose limited trans-cleavage activity has restricted its use in detection assays. SCas9 extends that platform to new target types and sensitivity levels.
The modular design could enable faster, more sensitive detection of viral and cancer-related nucleic acids in clinical samples. Commercial availability and regulatory review timelines have not been reported.
The takeaway
Modular guide RNA design is one way to expand CRISPR-based detection beyond its original limits. Readers following diagnostic technology should watch for independent validation of the clinical results.
Further reading
For related coverage, see the Life Sciences section.
Source note: This article includes information reported by Nature.







